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years—from the statutory health insurance (SHI), family and societal perspec-
tives— the number of AD cases, the direct medical, non-medical, and productivity
loss costs, and quality adjusted life-year (QALY) in infant receiving each formula
type for 4 months. The model included the following health states: disease free,
mild, moderate, and severe AD, and death. Efficacy estimates were based on the
German Infant Nutritional Intervention trial. Outcomes were discounted at 3% and
reported as cost per QALY gained and per avoided cases of AD. Extensive deter-
ministic and probabilistic sensitivity analyses (SA) were performed. RESULTS: In
the base case, pHF-W resulted in 0.016 (95% CI: 0.0066; 0.0249) QALY gained and 0.14
AD cases avoided per patients relative to SF, with corresponding estimated incre-
mental saving (SHI perspective) of €70.14 (95%CI: €16.26; €145.94;) per patient.
pHF-W resulted in 0.006 (95% CI: 0.0004; 0.0149) QALY gained and 0.04 AD cases
avoided per patients relative to eHF-W, with corresponding estimated incremental
saving (SHI perspective) of €424 (95%CI: €106.94; €848.26) per patient. Univariate SA
revealed that incremental QALYS and costs were most sensitive to changes in the
relative risk of developing AD up to one year when PHF is compared to SF and
reimbursement rates of formula for prevention. CONCLUSIONS: AD prevention
with pHF-W is a cost-effective strategy compared to SF and eHF-W.
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OBJECTIVES:Allergic rhinitis due to ragweed pollen is characterized by rhinorrhea,
itching, and nasal congestion. Methods of ragweed control, such as cutting and
mowing, are important to reduce the atmospheric concentration of pollen, thus
reducing the severity of AR symptoms and improving patients’ quality of life. The
aim of this study was to assess the economic impact of an intensive concerted
intervention mode (CIM) compared to a minimal intervention mode (MIM) in a
Quebec provincial context. METHODS: A cost-utility analysis was performed ac-
cording to a societal perspective. A time horizon of one month was chosen, which
correspond to the symptomatic period of AR due to ragweed pollen. CIM and MIM
were applied in two comparable cities from Quebec. The target population was
composed of people living in both cities, with a focus on patients suffering from AR
related to ragweed pollen. Clinical data were obtained from the Rhinoconjunctivitis
Quality of Life Questionnaire (RQLQ) and were converted into utility values using
the method proposed by Keiding and Jorgenson. Costs considered in this economic
evaluation were those necessary for the mobilization and sensitization of commu-
nity sectors, equipment, and additional typical methods of ragweed control.
RESULTS: RQLQ scores were obtained from 227 patients (106 for CIM and 121 for
MIM). For the population where the CIM was adopted, total cost of interventions
was CDN$60,603 and a gain of 10.15 QALYs was estimated. In the city with the MIM,
there were no additional costs and a decrease of 0.40 QALY was observed. The
incremental cost-utility ratio was estimated at CDN$5744/QALY. CONCLUSIONS:
This economic evaluation demonstrates that a CIM is a cost-effective strategy
compared to a MIM. Results of this study support the adoption of intensive inter-
vention programs in the control of AR due to ragweed pollen.
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OBJECTIVES: To assess the effect of subcutaneous-allergen-specific-immunother-
apy (SCIT) on disease severity classifications, number of days affected and sick
days per year on patients with grass-pollen and/or house dust mite (HDM) induced
allergic rhino-conjunctivitis (RC) and/or asthma (A). METHODS: A total of 248 pa-
tients started SCIT; an intension to treat approach was applied. The disease specific
Rhino-conjunctivitis Quality of Life Questionnaire (RQLQ) and the two generic
health-related quality of life (HRQoL) instruments 15D and EQ-5D were used. The
outcome measures included change in; disease severity classifications, RQLQ-
scores, number of days with symptoms, number of sick days, change in generic
HRQoL and Quality-Adjusted-Life-Years (QALY). RESULTS: The disease severity
classifications showed significantly improved disease control. Mean RQLQ-score
was reduced from 3.02 at baseline to 2.00 at follow-up. Average annual days with
symptoms were reduced from 189 days to 145 days whilst annual sick days were
reduced from 3.7 to 1.2 days. The 15D-score increased from 0.83 to 0.86 and the
EQ-5D-score from 0.70 to 0.77, which indicated an annual gain per patient of 0.03-
0.06 QALY. CONCLUSIONS: Allergic patients suffering from RC alone or RC and A
experience significantly increased HRQoL, when treated with SCIT for one year.
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OBJECTIVES: To examine correlates of non-adherence to drug therapy among
COPD patients in 5EU. METHODS: The study included data from the 2011 5EU
(N57,512) National Health and Wellness Survey, a survey representative of the
adult populations in France, Germany, Italy, Spain, and UK. Patients self-reported
physician diagnosis of COPD, chronic bronchitis, or emphysema and indicated they
were currently taking a prescription regimen for their condition. Adherence was
measured using the Morisky Adherence Scale. T-tests and chi-square tests were
used to assess differences between adherent and non-adherent patients. A binary
logistic regression model was used to determine patient characteristics indepen-
dently associated with non-adherence. Sex, age, smoking, alcohol use, Charlson
Comorbidity Index (CCI), out of pocket costs for prescriptions, use of cost saving
strategies (CSS), self-reported COPD severity, employment, income, number of co-
morbid conditions, and country were included as predictors. RESULTS: Of 1,263
respondents using a COPD medication, 30% (n375) reported at least one non-
adherent behavior. Bivariate comparisons revealed that non-adherent patients
were more likely to smoke and use CSS than adherent patients (49% vs. 36% and
48% vs. 32%, respectively; ps0.001). Adherent patients were also older (57.9 vs.
52.3) and experienced more severe COPD (17% vs. 9%; ps0.001). In the regression
model, age (OR: 1.02, 95% CI: 1.01, 1.03) and severe COPD (OR: 1.90, 95% CI: 1.21, 2.99)
were positively associated with adherence (ps0.01), while smoking (OR: 0.66, 95%
CI: 0.51, 0.86) and use of CSS (OR: 0.61, 95% CI: 0.46, 0.81) had negative associations
(ps0.01). No other variables in the model were associated with adherence.
CONCLUSIONS: In 5EU, advanced age and severe COPD are associated with in-
creased adherence, while smoking and CSS with are associated with decreased
adherence. Physicians need to target their younger, less severe COPD patients to
encourage greater adherence to therapy.
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OBJECTIVES: To assess the impact of the community pharmacy Spiriva New To
Therapy (SNTT) compliance program on adherence and persistence. METHODS:
Patients presenting at participating community pharmacies with their first script
for tiotropium were invited to participate in a pharmacist intervention involving
two 10 minute protocol based coaching sessions, one month apart. Records were
extracted of tiotropium scripts dispensed for all patients enrolled in the SNTT
program over the following 12 months. Adherence was assessed by MPR over the
first 6 months. Patients were considered to have ceased tiotropium if there was a
three month gap in dispensed scripts. Time to cessation of tiotropium treatment
was assessed using the Kaplan-Meier method. The SNTT program was compared
with persistence curves derived from a 10% random sample of tiotropium patients
using the Australian prescription claims database (SPBS). RESULTS: A total of 246
patients enrolled in the SNNT program; 48% completed Session #1, while 52% com-
pleted both Sessions. Over the first 6 months, SNTT program patients collected 5.2
tiotropium scripts indicating satisfactory adherence (MPR  87% vs 55%); 2% of
SNTT patients ceased tiotropium after the first prescription (SPBS37%), while just
38% (63%) had stopped after 10 months. Persistence by patients completing two
sessions was slightly better than those completing one. CONCLUSIONS: A phar-
macist intervention involving two short protocol based coaching sessions signifi-
cantly reduced the early cessation of tiotropium. A total of 35% to 40% more SNTT
program patients were persistent than the Australian SPBS population at 3-6
months. MPR was significantly improved.
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OBJECTIVES: Hereditary angioedema due to C1 inhibitor deficiency (HAE) is a rare
but serious disease marked by swelling attacks in various areas of the body. The
HAE Burden of Illness Study-Europe (HAE-BOIS-Europe) addresses the gaps in our
knowledge of the humanistic and economic impact of HAE in Europe. We report the
economic results. METHODS: This cross-sectional study was conducted in Spain
(ES), Denmark (DK), and Germany (DE), and was open to patients aged 12 years,
with a diagnosis of HAE-I or HAE-II. Data collection included a survey on individu-
als’ direct and indirect resource utilization, and the impact of HAE on work, school
and other activities. RESULTS: A total of 186 patients participated. From 84-100%
across countries reported having medication at home to treat attacks, although
48%, 25%, and 23% in ES, DK, and DE, respectively, still received care at a treatment
facility or saw a physician for their most recent attack; 21%, 18%, and 0%, respec-
tively, visited an emergency department. On a 0.0-10.0 (higher worse) rating scale
of the impact of the attack on ability to perform daily activities, patients reported a
mean score of 5.0; this did not vary significantly by site of attack. Overall, 24% of
patients missed time from work/school during the most recent attack, missing a
mean of 2.9 days, and 29% missed time from work/school between attacks over the
past 6 months, missing a median of 2.0 days. Overall, 59% required carer help over
the past 6 months, with a corresponding detriment to the carers’ work and/or
leisure time. Overall, 48% of patients reported that HAE has hindered their career
and/or educational advancement. CONCLUSIONS: The HAE-BOIS-Europe survey
has highlighted the substantial economic burden of HAE, which encompasses
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medical resource use, impact on productivity for both patients and carers, and
detrimental effects on education and careers.
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OBJECTIVES: Idiopathic Pulmonary Fibrosis (IPF) is a rare, irreversible and eventu-
ally fatal fibrosing lung disease. Cough and dyspnea are major symptoms. The
study objective was to assess the content validity of the Cough and Sputum As-
sessment Questionnaire (CASA-Q) cough domains and the UCSD Shortness of
Breath Questionnaire (SOBQ), instruments developed for use in chronic obstructive
pulmonary disease, when used in patients with IPF. METHODS: Cross-sectional,
qualitative study with cognitive interviews in patients with IPF. Study outcomes
included relevance, comprehension of item meaning, understanding of the in-
structions, recall period, response options, and concept saturation. RESULTS: In-
terviews were conducted with 18 patients. The mean age was 68.9 years (SD 11.9),
78% were male and 89% were Caucasian. The mean time since IPF diagnosis was 2.4
years (SD 1.6). Most participants (89%) found the CASA-Q cough domain items to be
highly relevant to their condition. The intended meaning of the items was clearly
understood by most of the participants (89-100%). All participants understood the
CASA-Q instructions; the correct recall period was reported by 89% of the patients,
and the response options were understood by 76%. Most participants (83%) re-
ported positive feedback for the SOBQ; those who did not were symptom free and
hence had no limitation in activities to report. The intended meanings of the items
were relevant and clearly understood by all participants. Participants understood
the instructions (83%) and all patients understood the response options. The recall
period produced varying responses, based on the type of activity performed. No
concepts were missing, suggesting that saturation was demonstrated for both
measures. CONCLUSIONS: Content validity and saturation for the CASA-Q cough
domain and SOBQ was established with items perceived as relevant to measure
symptoms of IPF. The results of this study support the use of these instruments in
IPF clinical trials.
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OBJECTIVES: To evaluate disease-specific quality of life (QoL) in children with
asthma according to patients’ and their parents’ perspective. METHODS: Hungar-
ian version of the Standardised Paediatric Asthma Quality of Life Questionnaire
(PAQLQ(s)) and the Paediatric Asthma Caregiver’s Quality of Life Questionnaire (PACQLQ)
were completed. The minimal important difference in the PAQLQ total score is 0.5
on the 7-point Likert scale, higher scores indicate better QoL. Asthma control was
assessed by Asthma Control Questionnaire (ACQ); Forced Expiratory Volume in 1 sec-
ond (FEV1) was measured via spirometry. RESULTS: A total of 125 children (7-17
years of age) and their caregivers completed the questionnaires. Overall PAQLQ
score was 5.740.97, overall PACQLQ score was 5.321.22 (r0.83), mean ACQ score
was 1.650.8 and mean FEV1 was 100.7114.91. PACQLQ scores were statistically
(p0.001) and clinically significantly lower, than PAQLQ scores. Correlations be-
tween FEV1 and overall score of PAQLQ(s) (r-0.15) and overall PACQLQ score (r-
0.005) were weak and not significant. The association between ACQ and total score
of PAQLQ(s)(r-0.64, p0.01) was moderate. CONCLUSIONS: Our participants had
poor asthma control despite their good lung function. Weak relationship was found
between spirometry and QoL according to patients’ and caregivers’ opinion; how-
ever QoL correlated only moderately with the level of asthma control. PAQLQ is able
to detect small but clinically important changes that children experience as a result
of the treatment or as a part of the natural fluctuation of their asthma, it provides
additional valuable information for clinical practice; children aged over 7 can pro-
vide reliable data on their Qol, where as parents often do not rate their children’s
Qol appropriately.
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OBJECTIVES: The Smoking Cessation Quality of Life (SCQoL) questionnaire as-
sesses the change in well-being and functioning associated with smoking cessa-
tion. The SCQoL includes 14 questions. This study aims to adapt the SCQoL into
Turkish language and culture and, check the reliability and validity of the inven-
tory culturally. METHODS: The original instrument was forward then back-trans-
lated by two independent translators. A small sample consisting of 42 people was
used to check the initial comprehension and convenance. Cronbach’s Alpha was
used to assess reliability and factor analysis to assess dimensionality. The Euro-
Qol-5D questionnaire and corresponding Visual Analogue Scales were used for
concurrent validity.RESULTS:A total of 152 people participated in this study. 55.9%
of them were female, 44.1% of them being male. Mean age was 24.3. The internal
consistency coefficient (Cronbach’s alpha) of SCQoL was 0.771. Factor analysis of
the scale revealed that it was composed of four factors and accounting for 67% of
the total variance. Correlations were moderate with EuroQol and VAS.
CONCLUSIONS: The culturally adapted to Turkish SCQoL has good validity and
reliability, making it a potentially useful outcome measure in determining the
effect of quality of life of people in Turkey.
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OBJECTIVES: Pulmonary arterial hypertension (PAH) is a chronic, debilitating dis-
ease characterized by an increase in blood pressure in the pulmonary arteries and
is associated with a burdensome low tolerance to exercise. Treprostinil is indicated
in the treatment of PAH in patients with New York Heart Association Class II-IV
symptoms and is available in one of two forms: infused or inhaled. The present
study determined the preference among members of the general public for one
treatment delivery option over the other, as well as the willingness-to-pay (WTP)
for the inhaled option. METHODS: An online survey of members of the general
public, 18 years of age or older, in the province Ontario, Canada, was conducted by
presenting descriptive and clinical information on each treatment delivery option,
ascertaining the participants’ preference for one option over the other, and, by
inviting participants who opted for the inhaled form to take part in a bidding game
evaluating their WTP in terms of additional monthly insurance premiums to en-
sure that inhaled treprostinil would be covered by a hypothetical insurance
scheme. Descriptive statistics and sub-group analyses based on demographic char-
acteristics were calculated with regards to preference and WTP. RESULTS: The
recruited population was more likely to be female, younger and with a higher
yearly household income, when compared to the population of Ontario. Of the 386
survey participants, 85.8% preferred the inhaled treatment option, with no signif-
icant differences in terms of preference observed across age or gender. The ob-
served median (minimum, maximum, mode) and mean (95% confidence interval)
WTP in monthly insurance premiums were CAD21.50 (CAD0, CAD200, CAD50) and
CAD37.25 (CAD32.51, CAD41.99), respectively; sub-group analyses based on gender,
age or yearly household income yielded no significant differences. CONCLUSIONS:
Inhaled treprostinil appears to be preferred over infused treprostinil and is associ-
ated with relatively high WTP for insurance premiums.
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OBJECTIVES: Pharmaceutical companies are increasingly shifting from a product-
centered to a customer and service-centered culture and many companies have
developed disease management programs for illnesses like asthma, COPD, diabe-
tes, arthritis, depression etc. Such programs come in all shapes and sizes and their
main aim is to improve the quality of care are reduce hospital costs. However, there
is insufficient evidence of cost-effectiveness of disease management programs.
Aim: The aim of this study is to review the impact of COPD disease management
(COPD-DM) programs on health care costs and outcomes. We also investigated the
impact of disease-, intervention-, and study-characteristics. METHODS: We con-
ducted a systematic review of cost-effectiveness studies of COPD-DM. The results
were grouped by study, intervention and disease characteristics and, where feasi-
ble, included in a random-effects meta-analysis. RESULTS: We included 16 papers
describing 11 studies. The meta-analysis showed that COPD-DM decreased the RR
of hospitalizations (RR: 0.71 [95CI: 0.53-0.96]), and led to a reduction of hospitaliza-
tion costs (€1093 [95CI: €2052-€133]) and average health care savings were €922
[95CI: €1549-€295] per patient. These savings have to be weighed against the costs
of developing, implementing and managing the DM program. There was substan-
tial heterogeneity. DM showed greater savings in hospital costs in studies including
severe COPD patients (GOLD stage 3). Savings were also greater when COPD-DM
programs addressed 3 or more components of the Chronic Care Model and in
studies from non-EU origin. CONCLUSIONS: DM decreased the risk of hospitaliza-
tion and health care costs (excluding program costs), but results varied by study-,
intervention-, and disease-characteristics. Future studies should more explicitly
include the overhead costs of running these DM programs.
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OBJECTIVES: Respiratory Syncytial virus (RSV) is the leading cause of respiratory
tract infections. Efficacy of Palivizumab in reducing RSV related hospitalizations
has been proven in preterm born infants and children with congenital heart dis-
ease (CHD) or bronchopulmonary dysplasia (BPD). However, the high costs of
Palivizumab may limit its use. This study described the characteristics of Palivi-
zumab users in the Netherlands and assessed the determinants of receiving Palivi-
zumab among infants with an indication according to the label. METHODS: Data
for this study were obtained by linking the PHARMO database network, which
includes detailed information on drug dispensing and hospitalization histories,
and The Netherlands Perinatal Registry, including perinatal medical case records.
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